Saba Capital discloses 6.08% GLV stake, 754,115 shares owned

Saba Capital Management, together with Saba Capital Management GP, LLC and Boaz R. Weinstein, filed Amendment No. 3 to Schedule 13D on Clough Global Dividend & Income Fund (GLV).

Rhea-AI Filing Summary

Saba Capital Management, together with Saba Capital Management GP, LLC and Boaz R. Weinstein, filed Amendment No. 3 to Schedule 13D on Clough Global Dividend & Income Fund (GLV). The group reports beneficial ownership of 754,115 Common Shares, representing 6.08% of the class, based on 12,409,683 shares outstanding as of 4/30/25.

The reporting persons have shared voting power over 754,115 shares and shared dispositive power over 754,115 shares, with no sole voting or dispositive power. Approximately $7,492,642 was paid to acquire the reported shares. The filing lists 10/21/2025 as the date of the event requiring the amendment and notes recent open‑market transactions are detailed in Schedule A. The amendment updates Items 3, 5, and 7; Item 4 (Purpose of Transaction) is marked Not Applicable.

Insights

Ownership & Activism Analyst

Saba reports a 6.08% GLV stake with shared voting power.

Saba Capital and affiliates disclose 6.08% beneficial ownership in GLV, totaling 754,115 shares, with shared voting and dispositive power. The ownership percentage is calculated against 12,409,683 shares outstanding as of 4/30/25.

Acquisitions were funded by investor subscriptions, capital appreciation, and ordinary-course margin, with about $7,492,642 paid for the position. Item 4 is Not Applicable, indicating no stated plans or proposals in this amendment.

The filing is primarily informational. Any impact depends on future holder actions or additional disclosures; timing is not specified in the provided excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in GLV does Saba Capital (GLV) report in this 13D/A?

Saba reports beneficial ownership of 754,115 Common Shares, equal to 6.08% of the class.

What share count did Saba use to calculate its 6.08% GLV ownership?

The percentage is based on 12,409,683 shares outstanding as of 4/30/25.

What voting and dispositive powers does Saba report for GLV?

Saba reports shared voting power of 754,115 and shared dispositive power of 754,115, with no sole power.

How much did Saba pay to acquire its GLV position?

Approximately $7,492,642 was paid to acquire the reported shares.

What is the event date for this GLV Schedule 13D/A filing?

The date of the event requiring the filing is 10/21/2025.

Does the filing state a purpose for Saba’s GLV investment?

Item 4 (Purpose of Transaction) is Not Applicable in this amendment.

Which items are amended in this 13D/A for GLV?

The amendment updates Items 3, 5, and 7.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/22/2025 - 11:33 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

Clough Global Dividend & Income Fund

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

18913Y103

(CUSIP Number)

Saba Capital Management, L.P.
405 Lexington Avenue, 58th Floor, Attention: Michael D'Angelo
New York, NY, 10174
(212) 542-4635

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/21/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 18913Y103

1

Name of reporting person

Saba Capital Management, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 754,115.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 754,115.00

11

Aggregate amount beneficially owned by each reporting person

754,115.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.08 %

14

Type of Reporting Person (See Instructions)

PN, IA

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 12,409,683 shares of common stock outstanding as of 4/30/25, as disclosed in the company's N-CSRS filed 7/7/25.

SCHEDULE 13D

CUSIP No. 18913Y103

1

Name of reporting person

Boaz R. Weinstein

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 754,115.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 754,115.00

11

Aggregate amount beneficially owned by each reporting person

754,115.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.08 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 12,409,683 shares of common stock outstanding as of 4/30/25, as disclosed in the company's N-CSRS filed 7/7/25.

SCHEDULE 13D

CUSIP No. 18913Y103

1

Name of reporting person

Saba Capital Management GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 754,115.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 754,115.00

11

Aggregate amount beneficially owned by each reporting person

754,115.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.08 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 12,409,683 shares of common stock outstanding as of 4/30/25, as disclosed in the company's N-CSRS filed 7/7/25.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Shares, no par value
(b)	Name of Issuer: Clough Global Dividend & Income Fund
(c)	Address of Issuer's Principal Executive Offices: 1700 Broadway, Suite 1850, Denver, COLORADO , 80290.
Item 1 Comment: This Amendment No. 3 amends Items 3, 5, and 7.
Item 2.	Identity and Background
(a)	This Schedule 13D/A is being jointly filed by: (i) Saba Capital Management, L.P., a Delaware limited partnership ("Saba Capital"); (ii) Saba Capital Management GP, LLC, a Delaware limited liability company ("Saba GP"); and (iii) Mr. Boaz R. Weinstein ("Mr. Weinstein"), (together, the "Reporting Persons"). Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed as an admission that any Reporting Person is, for the purposes of Sections 13 of the Securities Exchange Act of 1934, the beneficial owner of the Common Shares reported herein.
(b)	The address of the business office of each of the Reporting Persons is 405 Lexington Avenue, 58th Floor, New York, New York 10174.
(c)	The principal business of: (i) Saba Capital is to serve as investment manager to private and public investment funds and/or accounts, (ii) Saba GP is to serve as general partner of the Saba Capital and other affiliated entities, and (iii) Mr. Weinstein, an individual, is managing member of the general partner of Saba Capital and other affiliated entities.
(d)	The Reporting Persons have not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	The Reporting Persons have not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.
(f)	Saba Capital is organized as a limited partnership under the laws of the State of Delaware. Saba GP is organized as a limited liability company under the laws of the State of Delaware. Mr. Weinstein is a citizen of the United States.
Item 3.	Source and Amount of Funds or Other Consideration
	Funds for the purchase of the Common Shares were derived from the subscription proceeds from investors and the capital appreciation thereon and margin account borrowings made in the ordinary course of business. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the account, which may exist from time to time. Since other securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the Common Shares reported herein. A total of approximately $7,492,642 was paid to acquire the Common Shares reported herein.
Item 4.	Purpose of Transaction
	Not Applicable.
Item 5.	Interest in Securities of the Issuer
(a)	See the Reporting Persons section of this Schedule 13D/A for the aggregate number of Common Shares and percentages of the Common Shares beneficially owned by each of the Reporting Persons. The percentages used herein are calculated based upon 12,409,683 shares of common stock outstanding as of 4/30/25, as disclosed in the company's N-CSRS filed 7/7/25.
(b)	See the Reporting Persons section of this Schedule 13D/A for the number of Common Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
(c)	The transactions in the Common Shares effected by the Reporting Persons within the past sixty days prior to 10/21/25, the date of the event which required filing of this Schedule 13D/A, which were all in the open market, are set forth in Schedule A, and are incorporated herein by reference.
(d)	The funds and accounts advised by Saba Capital have the right to receive the dividends and proceeds of sales from the Common Shares.
(e)	Not Applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not Applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 3 - Schedule A

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Saba Capital Management, L.P.

Signature:	/s/ Michael D'Angelo
Name/Title:	General Counsel
Date:	10/22/2025

Boaz R. Weinstein

Signature:	/s/ Michael D'Angelo
Name/Title:	Authorized Signatory
Date:	10/22/2025

Saba Capital Management GP, LLC

Signature:	/s/ Michael D'Angelo
Name/Title:	Attorney-in-fact*
Date:	10/22/2025

Comments accompanying signature:

Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823